uniQure (QURE): Gene Therapy Progress in Hemophilia B – Equities.com
Equities.com |
uniQure (QURE): Gene Therapy Progress in Hemophilia B
Equities.com uniQure (Nasdaq: QURE) is developing gene therapy treatments for hemophilia B (whose patients are deficient in, or have defective, clotting factor IX), Huntington's disease and cardiovascular disease. Its platform uses adeno-associated virus (AAV … |
